(Q49164024)

13 June 2018

title

A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. (English)

1 reference

13 June 2018

1 reference

1 reference

Y Sasaki

1

1 reference

13 June 2018

H Hakusui

2

1 reference

13 June 2018

S Mizuno

3

1 reference

13 June 2018

M Morita

4

1 reference

13 June 2018

T Miya

5

1 reference

13 June 2018

K Eguchi

6

1 reference

13 June 2018

T Shinkai

7

1 reference

13 June 2018

T Tamura

8

1 reference

13 June 2018

Y Ohe

9

1 reference

13 June 2018

N Saijo

10

1 reference

13 June 2018

publication date

1 January 1995

1 reference

13 June 2018

number of pages

10

1 reference

Japanese Journal of Cancer Research

inferred from page(s)

published in

1 reference

13 June 2018

volume

86

1 reference

13 June 2018

issue

1

1 reference

13 June 2018

page(s)

101-110

1 reference

13 June 2018

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhi

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

A pharmacokinetic analysis program (multi) for microcomputer

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Toxicity and response criteria of the Eastern Cooperative Oncology Group

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Lethal activity of camptothecin sodium on human lymphoma cells.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2

14 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1349-7006.1995.TB02994.X

Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920579

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 December 2018

1 reference

12 December 2020

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

12 December 2020

Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse

1 reference

12 December 2020

Nonlinear pharmacokinetics of CPT-11 in rats

1 reference

12 December 2020

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

12 December 2020

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11

1 reference

12 December 2020

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

12 December 2020

Phase I study of CPT-11 and etoposide in patients with refractory solid tumors

1 reference

12 December 2020

Toxicity of camptothecin (NSC-100880)

1 reference

12 December 2020

Treatment of malignant melanoma with camptothecin (NSC-100880)

1 reference

12 December 2020

Action of 7-ethylcamptothecin on tumor cells and its disposition in mice

1 reference

12 December 2020

10.1111/J.1349-7006.1995.TB02994.X

Identifiers

DOI

1 reference

13 June 2018

PMC publication ID

5920579

1 reference

13 June 2018

PubMed publication ID

7737901

1 reference

13 June 2018